SMT201400005B - Composto anticancro e composizione farmaceutica che l contiene - Google Patents
Composto anticancro e composizione farmaceutica che l contieneInfo
- Publication number
- SMT201400005B SMT201400005B SM201400005T SM201400005T SMT201400005B SM T201400005 B SMT201400005 B SM T201400005B SM 201400005 T SM201400005 T SM 201400005T SM 201400005 T SM201400005 T SM 201400005T SM T201400005 B SMT201400005 B SM T201400005B
- Authority
- SM
- San Marino
- Prior art keywords
- pharmaceutical composition
- cancer compound
- cancer
- compound
- pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0902392A FR2945535B1 (fr) | 2009-05-18 | 2009-05-18 | Compose anticancereux et composition pharmaceutique le contenant |
| PCT/FR2010/050948 WO2010133794A1 (fr) | 2009-05-18 | 2010-05-17 | Compose anticancéreux et composition pharmaceutique le contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201400005B true SMT201400005B (it) | 2014-03-07 |
Family
ID=40973187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201400005T SMT201400005B (it) | 2009-05-18 | 2014-01-16 | Composto anticancro e composizione farmaceutica che l contiene |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US9073917B2 (xx) |
| EP (1) | EP2432766B1 (xx) |
| JP (1) | JP5656981B2 (xx) |
| KR (1) | KR20120032483A (xx) |
| CN (1) | CN102459193B (xx) |
| AR (1) | AR076686A1 (xx) |
| AU (1) | AU2010251013B2 (xx) |
| BR (1) | BRPI1012201A2 (xx) |
| CA (1) | CA2762233C (xx) |
| CL (1) | CL2011002930A1 (xx) |
| CO (1) | CO6400138A2 (xx) |
| CY (1) | CY1114850T1 (xx) |
| DK (1) | DK2432766T3 (xx) |
| EA (1) | EA021084B1 (xx) |
| ES (1) | ES2430989T3 (xx) |
| FR (1) | FR2945535B1 (xx) |
| HK (1) | HK1167388A1 (xx) |
| HR (1) | HRP20130959T1 (xx) |
| IL (1) | IL216361A0 (xx) |
| JO (1) | JO2852B1 (xx) |
| MA (1) | MA33356B1 (xx) |
| ME (1) | ME01542B (xx) |
| MX (1) | MX2011012356A (xx) |
| MY (1) | MY152995A (xx) |
| NZ (1) | NZ596464A (xx) |
| PL (1) | PL2432766T3 (xx) |
| PT (1) | PT2432766E (xx) |
| RS (1) | RS53002B (xx) |
| SG (1) | SG176169A1 (xx) |
| SI (1) | SI2432766T1 (xx) |
| SM (1) | SMT201400005B (xx) |
| TW (1) | TWI441822B (xx) |
| UY (1) | UY32644A (xx) |
| WO (1) | WO2010133794A1 (xx) |
| ZA (1) | ZA201108447B (xx) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2945535B1 (fr) | 2009-05-18 | 2011-06-10 | Sanofi Aventis | Compose anticancereux et composition pharmaceutique le contenant |
| FR2967413A1 (fr) * | 2010-11-17 | 2012-05-18 | Sanofi Aventis | Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora. |
| RS58700B1 (sr) | 2012-10-12 | 2019-06-28 | Broad Inst Inc | Gsk3 inhibitori i postupci njihove primene |
| KR20170016987A (ko) | 2014-07-01 | 2017-02-14 | 다케다 야쿠힌 고교 가부시키가이샤 | 헤테로시클릭 화합물 및 이들의 레티노이드-관련 희귀 수용체 (ｒｏｒ) 감마-ｔ 저해제로서의 용도 |
| EA201992359A1 (ru) | 2017-04-05 | 2020-03-12 | Дзе Брод Инститьют Инк. | Трициклические соединения в качестве ингибиторов киназы гликогенсинтазы-3 (gsk3) и их применение |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2391291A1 (en) | 1999-11-19 | 2001-05-25 | Abbott Laboratories | Tricyclic dihydropyrimidine potassium channel openers |
| JP2005501800A (ja) | 2001-02-02 | 2005-01-20 | 三菱ウェルファーマ株式会社 | ジヒドロピラゾロピリジン化合物およびその医薬用途 |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| AU2004264834A1 (en) * | 2003-06-13 | 2005-02-24 | Zentaris Gmbh | Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof |
| SI1746097T1 (sl) | 2005-07-20 | 2010-05-31 | Aventis Pharma Sa | dihidropiridin kondenzirani heterocikli postopek za njihovo pripravo njihova uporaba in sestavki ki jih vsebujejo |
| FR2945535B1 (fr) | 2009-05-18 | 2011-06-10 | Sanofi Aventis | Compose anticancereux et composition pharmaceutique le contenant |
-
2009
- 2009-05-18 FR FR0902392A patent/FR2945535B1/fr not_active Expired - Fee Related
-
2010
- 2010-05-16 JO JO2010163A patent/JO2852B1/en active
- 2010-05-17 SI SI201030384T patent/SI2432766T1/sl unknown
- 2010-05-17 AU AU2010251013A patent/AU2010251013B2/en not_active Ceased
- 2010-05-17 AR ARP100101705A patent/AR076686A1/es unknown
- 2010-05-17 MY MYPI2011005531 patent/MY152995A/en unknown
- 2010-05-17 CA CA2762233A patent/CA2762233C/fr not_active Expired - Fee Related
- 2010-05-17 PL PL10728768T patent/PL2432766T3/pl unknown
- 2010-05-17 CN CN201080032327.7A patent/CN102459193B/zh not_active Expired - Fee Related
- 2010-05-17 EA EA201171429A patent/EA021084B1/ru not_active IP Right Cessation
- 2010-05-17 JP JP2012511323A patent/JP5656981B2/ja not_active Expired - Fee Related
- 2010-05-17 EP EP10728768.2A patent/EP2432766B1/fr active Active
- 2010-05-17 MA MA34441A patent/MA33356B1/fr unknown
- 2010-05-17 RS RS20130444A patent/RS53002B/en unknown
- 2010-05-17 SG SG2011085529A patent/SG176169A1/en unknown
- 2010-05-17 ME MEP-2013-121A patent/ME01542B/me unknown
- 2010-05-17 DK DK10728768.2T patent/DK2432766T3/da active
- 2010-05-17 PT PT107287682T patent/PT2432766E/pt unknown
- 2010-05-17 TW TW099115713A patent/TWI441822B/zh not_active IP Right Cessation
- 2010-05-17 BR BRPI1012201A patent/BRPI1012201A2/pt not_active IP Right Cessation
- 2010-05-17 WO PCT/FR2010/050948 patent/WO2010133794A1/fr active Application Filing
- 2010-05-17 NZ NZ596464A patent/NZ596464A/en not_active IP Right Cessation
- 2010-05-17 ES ES10728768T patent/ES2430989T3/es active Active
- 2010-05-17 KR KR1020117030136A patent/KR20120032483A/ko active Search and Examination
- 2010-05-17 US US13/320,965 patent/US9073917B2/en not_active Expired - Fee Related
- 2010-05-17 MX MX2011012356A patent/MX2011012356A/es active IP Right Grant
- 2010-05-18 UY UY0001032644A patent/UY32644A/es not_active Application Discontinuation
-
2011
- 2011-11-14 IL IL216361A patent/IL216361A0/en unknown
- 2011-11-17 ZA ZA2011/08447A patent/ZA201108447B/en unknown
- 2011-11-18 CL CL2011002930A patent/CL2011002930A1/es unknown
- 2011-11-18 CO CO11157425A patent/CO6400138A2/es active IP Right Grant
-
2012
- 2012-08-15 HK HK12108002.5A patent/HK1167388A1/xx not_active IP Right Cessation
-
2013
- 2013-10-09 HR HRP20130959AT patent/HRP20130959T1/hr unknown
- 2013-10-17 CY CY20131100920T patent/CY1114850T1/el unknown
-
2014
- 2014-01-16 SM SM201400005T patent/SMT201400005B/xx unknown
-
2015
- 2015-06-02 US US14/728,846 patent/US9221817B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201700008B (it) | Composizione farmaceutica | |
| SMT201600181B (it) | Composti antiparassitari di diidroazolo e composizioni che li comprendono | |
| SMT201700095B (is) | Composizioni farmaceutiche per inalazione | |
| SMT201600350B (it) | Composizioni farmaceutiche | |
| DK3097925T3 (da) | Farmaceutisk sammensætning | |
| BRPI1004940A2 (pt) | composição farmacêutica | |
| SMT201600307B (it) | Composizione liposomiale | |
| DK3246018T3 (da) | Farmaceutisk sammensætning | |
| BRPI1011587A2 (pt) | compostos e composições terapèuticas | |
| BRPI0924135A2 (pt) | composição farmacêutica sólida compreendendo anlodipino e losartan | |
| BRPI1015939A2 (pt) | composição farmacêutica | |
| BR112012012108A2 (pt) | composição farmacêutica compreendendo propofol | |
| BRPI1012539A2 (pt) | composições farmacêuticas | |
| BRPI1013588A2 (pt) | composição | |
| BRPI1015474A2 (pt) | composição | |
| EE201300005A (et) | Ravimkoostis | |
| DK2285413T3 (da) | Farmaceutisk sammensætning | |
| IT1394400B1 (it) | Composizioni farmaceutiche | |
| FI20096058A0 (fi) | Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä | |
| BR112012000831A2 (pt) | compostos, composições farmacêuticas e métodos relacionados | |
| BRPI0921313A2 (pt) | composição farmaucêutica | |
| DK2391349T3 (da) | Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater | |
| CO6801722A2 (es) | Composiciones farmacéuticas | |
| BRPI1005290A2 (pt) | composição | |
| BR112012003149A2 (pt) | composição farmacêutica |